MARKET

REGN

REGN

Regeneron Pharmaceuticals
NASDAQ
718.36
-4.44
-0.61%
After Hours: 721.00 +2.64 +0.37% 19:45 12/05 EST
OPEN
723.00
PREV CLOSE
722.80
HIGH
736.15
LOW
717.26
VOLUME
798.45K
TURNOVER
--
52 WEEK HIGH
796.57
52 WEEK LOW
475.17
MARKET CAP
75.50B
P/E (TTM)
17.19
1D
5D
1M
3M
1Y
5Y
1D
Upstream Bio: Maintaining Buy Rating On Verekitug Success In Phase 2 CRSwNP Study
Seeking Alpha · 13h ago
Is Regeneron Still Attractive After Recent Pipeline Milestones and Valuation Upside Signals?
Simply Wall St · 16h ago
Jazz (JAZZ) Up 24.5% Since Last Earnings Report: Can It Continue?
NASDAQ · 18h ago
Regeneron Pharma Is Maintained at Buy by Canaccord Genuity
Dow Jones · 1d ago
Regeneron Pharma Price Target Raised to $1057.00/Share From $850.00 by Canaccord Genuity
Dow Jones · 1d ago
Canaccord Genuity Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $1057
Benzinga · 1d ago
Cathie Wood's Buys And Rumors Aside, Here's Why Crispr Therapeutics Is A Strong Buy
Seeking Alpha · 1d ago
Regeneron Pharma Price Target Raised to $850.00/Share From $725.00 by BMO Capital
Dow Jones · 1d ago
More
About REGN
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.

Webull offers Regeneron Pharmaceuticals Inc stock information, including NASDAQ: REGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, REGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading REGN stock methods without spending real money on the virtual paper trading platform.